Arrowhead Research Changes Name to Arrowhead Pharmaceuticals

Home/Newsroom/

Arrowhead Research Changes Name...

New website launched at www.arrowheadpharma.com,

ticker symbol remains ARWR

PASADENA, Calif.–(BUSINESS WIRE)–

Arrowhead Research Corporation (NASDAQ:ARWR) today announced that it has

changed its corporate name to Arrowhead Pharmaceuticals, Inc. The

company’s common stock will continue to trade on the NASDAQ Global

Select Market under the existing stock ticker symbol, ARWR. These shares

have been assigned a new CUSIP number of 04280A100. Holders of stock

certificates with the prior corporate name, need not take any action.

As part of this name change, the company has also launched a new

corporate website at www.arrowheadpharma.com

and a new Twitter handle @ArrowheadPharma.

Chris Anzalone, Ph.D., president and CEO of Arrowhead Pharmaceuticals,

said: “Now is the time to acknowledge that our key priorities are

increasingly focused on advancing products through clinical development

to bring innovative new medicines to patients. The name Arrowhead

Pharmaceuticals is more consistent with our stage of development as a

company and reflects the great progress we’re making on our broad

pipeline of RNAi-based drugs.”

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable

diseases by silencing the genes that cause them. Using a broad portfolio

of RNA chemistries and efficient modes of delivery, Arrowhead therapies

trigger the RNA interference mechanism to induce rapid, deep, and

durable knockdown of target genes. RNA interference, or RNAi, is a

mechanism present in living cells that inhibits the expression of a

specific gene, thereby affecting the production of a specific protein.

Arrowhead’s RNAi-based therapeutics leverage this natural pathway of

gene silencing. The company’s pipeline includes ARC-520 and ARC-521 for

chronic hepatitis B virus, ARC-AAT for liver disease associated with

alpha-1 antitrypsin deficiency, ARC-F12 for hereditary angioedema and

thromboembolic disorders, ARC-LPA for cardiovascular disease, and

ARC-HIF2 for renal cell carcinoma.

For more information please visit www.arrowheadpharma.com,

or follow us on Twitter @ArrowheadPharma.

To be added to the Company’s email list and receive news directly,

please visit

http://ir.arrowheadpharma.com/alerts.cfm.

Safe Harbor Statement under the Private Securities Litigation Reform

Act:

This news release contains forward-looking statements within the

meaning of the “safe harbor” provisions of the Private Securities

Litigation Reform Act of 1995. These statements are based upon our

current expectations and speak only as of the date hereof. Our actual

results may differ materially and adversely from those expressed in any

forward-looking statements as a result of various factors and

uncertainties, including our ability to finance our operations, the

future success of our scientific studies, our ability to successfully

develop drug candidates, the timing for starting and completing clinical

trials, rapid technological change in our markets, and the enforcement

of our intellectual property rights. Our most recent Annual Report on

Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of

the important risk factors that may affect our business, results of

operations and financial condition. We assume no obligation to update or

revise forward-looking statements to reflect new events or circumstances.

DYNAMIC POLYCONJUGATES is a trademark of Arrowhead

Pharmaceuticals, Inc.

Source: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
ir@arrowheadpharma.com
or
Investor

Relations:
The Trout Group
Chad Rubin
646-378-2947
ir@arrowheadpharma.com
or
Media:
Russo

Partners
Matt Middleman, M.D.
212-845-4272
matt.middleman@russopartnersllc.com

Source: Arrowhead Pharmaceuticals, Inc.

News Provided by Acquire Media